NCT06963281

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 285 (estimated)
• Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	IBI3020	Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection

Timeline

• Start date: 2025-04-29
• Primary completion: 2027-12-31
• Completion: 2028-03-31
• First posted: 2025-05-08
• Last updated: 2025-06-06

Locations

9 sites across 2 countries: United States, China

Regulatory

• FDA-regulated drug study